Prothrombin Complex Concentrate versus Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: Evidence Synthesis from the FARES-II Multicenter Randomized Clinical Trial and Related Studies
Posted inCardiology Clinical Updates General Surgery news

Prothrombin Complex Concentrate versus Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: Evidence Synthesis from the FARES-II Multicenter Randomized Clinical Trial and Related Studies

This review synthesizes evidence demonstrating that 4-factor prothrombin complex concentrate (4F-PCC) offers superior hemostatic efficacy and safety compared to frozen plasma in managing coagulopathic bleeding during cardiac surgery, supported by the recent FARES-II trial and corroborating clinical research.
Cryopreserved Versus Liquid-Stored Platelets in Surgical Bleeding: Insights from the CLIP-II Randomized Noninferiority Trial
Posted inClinical Updates General Surgery news

Cryopreserved Versus Liquid-Stored Platelets in Surgical Bleeding: Insights from the CLIP-II Randomized Noninferiority Trial

The CLIP-II trial evaluated dimethyl sulfoxide-cryopreserved platelets with extended shelf-life against conventional liquid-stored platelets in cardiac surgery bleeding, finding noninferiority was not established and cryopreserved platelets showed reduced hemostatic effectiveness despite similar safety profiles.
Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings
Posted inCardiology Diabetes & Endocrinology news

Metformin Exposure Associated with Up to 81% Lower 30‑Day Mortality After Cardiac Surgery in T2DM: A Critical Appraisal of AHA 2025 MIMIC‑IV Cohort Findings

A retrospective MIMIC‑IV cohort presented at AHA 2025 found perioperative metformin exposure in T2DM patients undergoing cardiac surgery associated with markedly lower 30‑, 90‑ and 360‑day mortality. Results are compelling but observational—randomized trials are needed to confirm causality and define perioperative use.
Pathogen-Reduced Red Blood Cells Are Safe in Cardiac Surgery: ReCePI Phase 3 Shows Noninferior AKI Rates
Posted inAnesthesiology Cardiology General Surgery news

Pathogen-Reduced Red Blood Cells Are Safe in Cardiac Surgery: ReCePI Phase 3 Shows Noninferior AKI Rates

The ReCePI randomized phase 3 trial found that amustaline/glutathione pathogen-reduced red blood cells produced similar rates of acute kidney injury compared with conventional transfusion after cardiac or thoracic-aorta surgery, with few treatment-emergent antibodies and no clinically significant hemolysis.